Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune disorder in which the immune system produces autoantibodies — predominantly warm-reactive IgG or cold-reactive IgM — that target red blood cell (RBC) surface antigens, triggering complement-mediated or Fcγ receptor-mediated destruction of erythrocytes. With an annual incidence of 1–3 per 100,000 and a prevalence exceeding approximately 50,000 cases in the United States, AIHA causes fatigue, dyspnea, pallor, jaundice, and — in severe or rapidly progressive cases — high-output heart failure and multi-organ ischemic injury [1].

Where conventional treatments fall short. First-line therapy with corticosteroids achieves an initial response in 70–85% of patients with warm AIHA, but sustained remission after tapering occurs in only 20–30%. Second-line options — rituximab, splenectomy, and immunosuppressants (mycophenolate mofetil, cyclophosphamide, azathioprine) — each carry significant limitations: rituximab yields a 50–60% initial response but a 30–40% relapse rate at 3 years; splenectomy carries a 1–2% lifetime risk of overwhelming post-splenectomy sepsis and a 30% late relapse rate; and long-term immunosuppression increases infection and malignancy risk [2]. For cold agglutinin disease (CAD), conventional options are even more limited — corticosteroids and splenectomy are largely ineffective, and rituximab monotherapy yields only a 45–55% response rate. A significant proportion of patients cycle through multiple therapies without durable, treatment-free remission.

The deeper problem is multi-level immune dysregulation. AIHA is not simply antibody-mediated RBC destruction. It involves a complex interplay of Th1/Th17 polarization with diminished regulatory T-cell (Treg) function, loss of B-cell tolerance to RBC self-antigens, complement cascade activation with membrane attack complex (MAC) formation, and impaired compensatory erythropoiesis — the bone marrow's attempt to replace destroyed RBCs is often inadequate due to inflammation-driven suppression of erythroid precursors [3]. Targeting any single pathway — as conventional therapies do — leaves the broader immune dysregulation intact.

MSC therapy targets multiple pathogenic mechanisms simultaneously. Rather than blocking a single receptor or depleting one cell population, mesenchymal stem cells (MSCs) engage the immune system at multiple checkpoints: they suppress autoreactive T-cell proliferation, restore Treg/Th17 balance, polarize macrophages from a pro-inflammatory M1 phenotype toward a reparative, RBC-sparing M2 phenotype, inhibit B-cell differentiation and autoantibody production, and secrete trophic factors — including erythropoietin (EPO), stem cell factor (SCF), and insulin-like growth factor-1 (IGF-1) — that directly support erythroid progenitor survival and RBC maturation [4]. This multi-target approach makes MSCs a uniquely compelling candidate for a disease driven by multi-level immune dysregulation and bone marrow stress.

What Is Autoimmune Hemolytic Anemia?

Autoimmune hemolytic anemia is an acquired disorder characterized by premature destruction of red blood cells (hemolysis) driven by autoantibodies directed against RBC surface antigens, resulting in anemia with a hemoglobin typically below 10 g/dL, elevated reticulocyte count, elevated lactate dehydrogenase (LDH), low haptoglobin, and a positive direct antiglobulin test (DAT, or Coombs test). The disease is classified by the thermal reactivity of the autoantibody: warm AIHA (wAIHA, ~70% of cases, IgG-mediated, optimal binding at 37°C), cold agglutinin disease (CAD, ~20%, IgM-mediated, optimal binding at 0–4°C), and mixed-type AIHA (~5–10%). Approximately 50% of AIHA cases are primary (idiopathic), while the remaining 50% are secondary to underlying conditions — most commonly lymphoproliferative disorders (CLL, NHL), systemic autoimmune diseases (SLE), infections (EBV, Mycoplasma pneumoniae, HIV), and certain medications [5].

The pathophysiology differs between warm and cold subtypes. In wAIHA, IgG autoantibodies (most commonly directed against Rh-related proteins) coat RBCs and trigger Fcγ receptor-mediated phagocytosis by splenic and hepatic macrophages — predominantly extravascular hemolysis. A subset of wAIHA involves complement activation (C3b deposition), leading to both extravascular clearance by hepatic Kupffer cells (via C3b receptors) and, rarely, intravascular hemolysis via MAC formation. In CAD, IgM autoantibodies (typically directed against the I/i carbohydrate antigens) bind RBCs in cooler peripheral circulation, fix complement (C1q → C3b), and upon return to warmer central circulation the IgM dissociates, leaving C3b-opsonized RBCs that are cleared by hepatic macrophages [6]. The bone marrow attempts to compensate with a 6–8 fold increase in erythropoiesis, but this compensatory response is often blunted by inflammatory cytokines (TNF-α, IFN-γ) that suppress erythroid progenitor proliferation and by functional iron deficiency from chronic hemolysis.

Clinically, patients present with progressive fatigue, exertional dyspnea, pallor, jaundice (from unconjugated hyperbilirubinemia), dark urine (hemoglobinuria in intravascular hemolysis), and splenomegaly. Severe anemia (hemoglobin <6–7 g/dL) can precipitate high-output cardiac failure, angina, and syncope — particularly in elderly patients with comorbidities. The mortality rate in severe, treatment-refractory AIHA is estimated at 10–15% over 5 years [7].

How MSC Therapy Helps Autoimmune Hemolytic Anemia

Restoring Treg/Th17 balance. The central immunological defect in AIHA — as in ITP and other organ-specific autoimmune diseases — is a collapse of peripheral tolerance driven by a shift from Treg-dominant to Th17-dominant CD4+ T-cell profiles. MSCs secrete TGF-β and prostaglandin E2 (PGE2), which directly induce naïve CD4+ T cells to differentiate into functional FoxP3+ Tregs while suppressing Th17 polarization via inhibition of RORγt expression and IL-6/STAT3 signaling. In a murine AIHA model (C57BL/6 mice immunized with rat RBCs), intravenous infusion of Wharton's jelly-derived MSCs increased splenic Treg frequency from 3.1% to 8.2% of CD4+ T cells and decreased Th17 cells from 2.8% to 1.0%, with a corresponding rise in hematocrit from 24.3 ± 3.1% to 41.8 ± 4.2% over 4 weeks [8].

Suppressing anti-RBC autoantibody production. MSCs inhibit B-cell proliferation, differentiation into antibody-secreting plasma cells, and immunoglobulin production through both contact-dependent mechanisms (PD-L1/PD-1 axis, Fas/FasL) and soluble factors (indoleamine 2,3-dioxygenase, hepatocyte growth factor, IL-10). In vitro, co-culture of MSCs with peripheral blood mononuclear cells from AIHA patients reduced anti-RBC IgG antibody production by 58% and anti-C3d deposition by 64% compared to untreated controls [9]. Direct B-cell suppression is especially relevant in AIHA because autoantibody titer correlates with hemolysis severity, and complete serological remission (negative DAT) — though uncommon with conventional therapy alone — is the most durable predictor of long-term treatment-free remission.

Modulating complement-mediated hemolysis. MSCs express and secrete complement regulatory proteins — including factor H, CD55 (decay-accelerating factor), and CD59 (protectin) — that inhibit complement activation at multiple steps of the cascade. MSC-derived factor H accelerates the decay of C3 convertase (C3bBb) and serves as a cofactor for factor I-mediated cleavage of C3b, reducing C3b deposition on RBC surfaces. In a rat model of complement-mediated hemolysis, intraperitoneal MSC administration reduced C3b deposition on circulating RBCs by 47% and decreased plasma free hemoglobin (a marker of intravascular hemolysis) by 62% compared to untreated controls [10]. This complement-modulatory property is particularly relevant for CAD and complement-positive wAIHA, where C3b-mediated hepatic clearance drives the majority of RBC destruction.

Promoting erythropoiesis and bone marrow recovery. Beyond immune modulation, MSCs support the hematopoietic niche directly. MSCs are the native stromal cells of the bone marrow and secrete SCF, EPO, IGF-1, and IL-3 — the key cytokines governing erythroid progenitor (BFU-E and CFU-E) survival, proliferation, and terminal differentiation into reticulocytes. In a murine AIHA model, MSC infusion increased bone marrow erythroid island density by 2.1-fold, the proportion of Ter119+ erythroid cells by 1.8-fold, and the reticulocyte count (a direct measure of new RBC production) from 4.2% to 9.8% at day 14 — demonstrating that MSC-supported erythropoiesis complements immune suppression to accelerate hematologic recovery [11].

Macrophage polarization away from RBC clearance. Splenic and hepatic macrophages are the primary effectors of RBC destruction in AIHA — splenic red pulp macrophages phagocytose IgG-coated RBCs, and hepatic Kupffer cells clear C3b-opsonized RBCs. MSCs reprogram macrophages from a pro-inflammatory M1 phenotype (CD80+, TNF-α+, high FcγR expression) to an anti-inflammatory, RBC-sparing M2 phenotype (CD163+, IL-10+, decreased FcγR expression) through secretion of PGE2 and TSG-6. In a murine AIHA model, MSC-treated animals showed a 2.5-fold increase in splenic M2 macrophages and a 58% reduction in RBC clearance rate measured by 51Cr-labeled RBC survival [12].

Clinical Evidence for MSC Therapy in AIHA

The clinical evidence base for MSC therapy in AIHA is nascent — substantially smaller than for ITP — but the shared immunological mechanisms and favorable safety profile of MSCs across dozens of autoimmune disease trials provide a compelling rationale. No dedicated AIHA MSC trial has been published as of 2026, but several lines of indirect clinical evidence support feasibility.

Case reports and small series. A 2021 case report by Li et al. described a 52-year-old woman with warm AIHA secondary to systemic lupus erythematosus, refractory to prednisone, rituximab, and mycophenolate mofetil over 4 years. She received three infusions of umbilical cord-derived MSCs (1 × 10⁶ cells/kg at 4-week intervals). At 6 months, hemoglobin rose from 7.2 to 12.8 g/dL, LDH normalized from 620 to 210 U/L, and the DAT decreased from 3+ to 1+ without additional immunosuppression. She remained in remission through 18 months of follow-up [13].

A 2022 case series by Zhang et al. reported 3 patients with cold agglutinin disease refractory to rituximab who received 4 infusions of Wharton's jelly-derived MSCs (1.5 × 10⁶ cells/kg monthly). At 12 months, 2 of 3 patients achieved a hemoglobin increase of >3 g/dL (from median 8.1 to 11.4 g/dL), with a corresponding decrease in cold agglutinin titer from 1:1024 to 1:128 in one patient and from 1:512 to 1:64 in the other. The third patient had a transient 6-week response before relapsing. No infusion reactions or serious adverse events were observed [14].

Evidence from related autoimmune cytopenias. The strongest indirect evidence comes from the ITP MSC literature, where a 2021 meta-analysis of 5 studies (89 patients with refractory ITP) reported a pooled overall response rate of 54% (95% CI: 42–66%) and a pooled complete response rate of 31% [15]. AIHA shares ITP's core immunological defects — Treg/Th17 imbalance, loss of B-cell tolerance, and macrophage-mediated peripheral destruction — and the MSC mechanisms that restore platelet counts in ITP (Treg induction, B-cell suppression, macrophage M2 polarization) are equally applicable to RBC preservation in AIHA. Additionally, MSCs have demonstrated efficacy in graft-versus-host disease (GVHD), an alloimmune condition that, like AIHA, involves donor-derived immune cells attacking host tissues — including hematopoietic cells. In steroid-refractory acute GVHD, MSC therapy achieves a 50–70% overall response rate across multiple Phase II/III trials, with responses driven by the same immunomodulatory pathways (Treg induction, Th17 suppression, macrophage polarization) relevant to AIHA [16].

Ongoing research. An open-label Phase I/II trial (NCT04812561) evaluating umbilical cord-derived MSCs in refractory autoimmune cytopenias — including AIHA, ITP, and Evans syndrome (combined AIHA + ITP) — began enrollment in 2024 at Xinqiao Hospital (Chongqing, China). The trial uses a dose-escalation design (0.5–2.0 × 10⁶ cells/kg) with 4 infusions over 8 weeks and a primary endpoint of hematologic response at 24 weeks. Results are expected in 2026–2027 and will provide the first prospective, systematically collected safety and efficacy data for MSCs in AIHA.

Why Consider MSC Therapy for AIHA? Potential Benefits

Durable, treatment-free remission as the goal. Unlike corticosteroids, which lose efficacy upon tapering, or rituximab, which requires repeated cycles as B cells repopulate, MSC therapy aims to reset immune tolerance — potentially enabling sustained hematologic remission without ongoing immunosuppression. In the Li et al. case report, the AIHA patient maintained a normal hemoglobin through 18 months without any maintenance therapy after a single course of MSCs [13]. While a single case is not generalizable, the durability seen in ITP MSC trials (42% complete response at 12 months in the Ma et al. study, with responses persisting through 18+ months of follow-up) supports the concept that MSC-induced immune tolerance can be sustained.

Multi-pathway mechanism matching multi-level disease. Conventional AIHA therapies target single pathways — corticosteroids broadly suppress inflammation, rituximab depletes CD20+ B cells, splenectomy removes the site of IgG-mediated RBC destruction. None simultaneously address the T-cell dysregulation, complement-mediated hemolysis, impaired erythropoiesis, and macrophage polarization that collectively drive chronic AIHA. MSCs engage all four — a mechanistic fit that aligns with the multi-level pathophysiology of treatment-refractory disease.

Favorable safety profile in autoimmune populations. Across more than 50 clinical trials of MSCs in autoimmune diseases totaling over 2,500 patients, no cases of ectopic tissue formation, malignant transformation, or MSC-related mortality have been reported. The most common adverse events are mild — transient fever (8–12% of infusions), headache (5–8%), and infusion-site reactions (3–5%) — and resolve within 24 hours [17]. This safety record is particularly relevant for AIHA patients who often have significant comorbidity burdens from chronic hemolysis, iron overload from transfusions, and prior immunosuppression.

Potential for treating secondary AIHA at its root cause. Approximately half of AIHA cases are secondary to an underlying condition — most commonly SLE, CLL, or other lymphoproliferative disorders. In secondary AIHA associated with SLE, MSC therapy may offer a dual benefit: suppressing anti-RBC autoantibody production while simultaneously treating the underlying lupus through the same Treg/Th17, B-cell, and macrophage mechanisms. The same rationale applies to AIHA secondary to Evans syndrome, where MSCs may address both the autoimmune hemolysis and the concurrent ITP through shared immunomodulatory pathways.

The MSC Treatment Journey for AIHA

Pre-treatment assessment. Before considering MSC therapy, patients undergo comprehensive evaluation: complete blood count with reticulocyte count and peripheral smear, direct antiglobulin test (DAT) with monospecific anti-IgG and anti-C3d, hemolysis markers (LDH, haptoglobin, indirect bilirubin), serum protein electrophoresis and immunofixation (to exclude lymphoproliferative disorders), cold agglutinin titer and thermal amplitude (if CAD is suspected), bone marrow biopsy (if myelodysplasia or marrow failure is suspected), and thorough infectious disease screening (HIV, HBV, HCV, EBV, CMV). This workup confirms the diagnosis, classifies the AIHA subtype, identifies any underlying secondary cause, and establishes baseline hematologic and immunologic parameters against which response can be measured.

Cell sourcing and preparation. At VELAR Center, MSCs are derived from Wharton's jelly of umbilical cord tissue — a perinatal source selected for its young biological age, robust proliferative capacity, potent immunomodulatory profile, and non-invasive collection (donated after healthy full-term cesarean delivery with maternal informed consent). Cells are expanded under cGMP conditions in an ISO Class 5 (Class-100) cleanroom, undergo rigorous quality control (≥95% CD73/CD90/CD105 expression, ≤2% CD34/CD45/HLA-DR, sterility, endotoxin <0.5 EU/mL, mycoplasma-free), and are delivered fresh and never-frozen within hours of final release testing — ensuring >95% cell viability at the time of administration without the viability loss (~10–20%) and DMSO toxicity associated with cryopreserved products.

Administration protocol. Based on protocols from ITP clinical trials and the small AIHA case series, a typical AIHA protocol involves intravenous infusion of 1–2 × 10⁶ MSCs per kilogram of body weight, administered over 30–60 minutes as an outpatient procedure. A course typically consists of 3–4 infusions spaced 2–4 weeks apart, with the rationale that repeated dosing sustains the immunomodulatory pressure needed to durably shift the Treg/Th17 ratio, suppress autoantibody production, and allow the bone marrow sufficient time to mount a compensatory erythropoietic response. Unlike PRP or growth-factor injections, the infused MSCs work systemically through paracrine signaling — they do not need to be delivered to a specific anatomical site.

Monitoring and expected timeline. Hematologic response is tracked through serial CBC with reticulocyte count, hemolysis markers (LDH, haptoglobin), and DAT strength at weeks 4, 8, 12, 24, and 52 post-treatment. Based on the ITP MSC literature and the available AIHA case data, the expected trajectory is: (1) stabilization of hemoglobin decline within 2–4 weeks through reduced macrophage-mediated RBC clearance; (2) reduction in hemolysis markers (LDH, reticulocyte count) by 4–8 weeks as autoantibody production is suppressed and complement activation is modulated; (3) meaningful hemoglobin increase (>2 g/dL above baseline) by 8–16 weeks as compensatory erythropoiesis restores RBC mass; and (4) potential sustained, treatment-free remission by 6–12 months in responders. Early treatment — before years of chronic hemolysis cause irreversible bone marrow niche damage and transfusion-related iron overload — appears to be associated with better outcomes, as observed in the ITP meta-analysis where disease duration <3 years predicted a 71% response rate versus 38% for longer-standing disease [15].

AIHA-Specific Considerations and Caveats

Subtype matters — warm vs. cold AIHA. The limited available evidence suggests that warm AIHA may respond more favorably to MSC therapy than cold agglutinin disease because its IgG-mediated pathophysiology depends more heavily on T-cell help, B-cell autoantibody production, and macrophage FcγR-mediated clearance — all processes that MSCs directly modulate. CAD, driven by IgM autoantibodies produced by a clonal or oligoclonal B-cell population with less T-cell dependence, may be less susceptible to MSC-mediated Treg/Th17 and B-cell modulation. The 2022 Zhang et al. case series in CAD showed responses in 2 of 3 patients, but the responses were partial and less dramatic than those reported in wAIHA — consistent with this mechanistic distinction [14].

Hemolytic crisis management. Patients with severe, rapidly progressive hemolysis (hemoglobin <6 g/dL, hemodynamic instability) require urgent conventional management — transfusion of least-incompatible RBCs, high-dose corticosteroids, and, in life-threatening cases, therapeutic plasma exchange or eculizumab for complement-mediated crises. MSC therapy is not a rescue treatment for acute hemolytic crisis; it is best positioned as a disease-modifying intervention for patients with chronic, treatment-refractory AIHA who are hematologically stable enough to wait the weeks-to-months required for immunomodulatory effects to translate into meaningful hematologic improvement.

Transfusion burden and iron overload. Many patients with chronic AIHA have received dozens to hundreds of RBC transfusions over years, resulting in secondary iron overload with hepatic, cardiac, and endocrine toxicity. Successful MSC therapy that achieves sustained remission can halt the transfusion requirement — but it does not reverse existing iron overload. Patients with significant transfusion histories should be evaluated for iron overload (serum ferritin, MRI T2* for liver and cardiac iron) and, if indicated, undergo iron chelation therapy in parallel with or following MSC treatment.

How to Evaluate Whether MSC Therapy Is Right for Your AIHA

MSC therapy is an investigational treatment for AIHA, and not every patient is an appropriate candidate. Key factors to weigh when evaluating the option include:

Candidate Profile: Who May Benefit Most

  • Warm AIHA (IgG-mediated, DAT IgG+). Stronger mechanistic rationale due to T-cell-dependent B-cell autoantibody production, macrophage FcγR-mediated clearance, and more favorable preclinical signal.
  • Refractory to at least two lines of conventional therapy (corticosteroids + rituximab with or without splenectomy/immunosuppressant), or intolerant of standard therapies due to side effects.
  • Disease duration <3 years. The ITP meta-analysis suggests better outcomes with earlier intervention before irreversible bone marrow niche damage accumulates.
  • Secondary AIHA with concurrent autoimmune disease (e.g., SLE-associated AIHA, Evans syndrome) where MSC therapy may address both the hemolysis and the underlying autoimmune condition.
  • No active lymphoproliferative malignancy requiring urgent chemotherapy or targeted therapy — the MSC safety profile in active malignancy is not well characterized.

Frequently Asked Questions

Is MSC therapy a cure for autoimmune hemolytic anemia?

No. MSC therapy is an investigational treatment that aims to reset immune tolerance, suppress anti-RBC autoantibody production, and promote erythropoiesis — potentially enabling durable, treatment-free hematologic remission. It is not a guaranteed cure. The limited AIHA-specific data (case reports and small series) show promising responses in some patients, but robust clinical trial evidence is not yet available. Patients should approach MSC therapy for AIHA with realistic expectations: it is a disease-modifying strategy under clinical investigation, not a curative intervention.

How much does MSC therapy for AIHA cost in Thailand?

MSC therapy for AIHA at established centers in Bangkok typically ranges from approximately $12,000 to $22,000 USD per treatment course, depending on cell dose, number of infusions, and the specific protocol. This is substantially lower than equivalent treatment in the United States or Europe ($25,000–$50,000+) for comparable quality standards. VELAR Center provides a detailed cost breakdown during the pre-treatment consultation, including the cell preparation laboratory fee, physician administration fee, pre-treatment workup, and follow-up monitoring. Patients should request an all-inclusive quote that covers the full treatment course.

What is the difference between MSC therapy for AIHA and a blood transfusion?

Blood transfusion is a supportive therapy that temporarily replaces destroyed RBCs — it addresses the consequence of AIHA (anemia) but does nothing to modify the underlying autoimmune process. MSC therapy aims to modify the disease itself by suppressing the anti-RBC autoantibody response, restoring immune tolerance, and supporting the bone marrow's own erythropoietic capacity. They are complementary, not competing, interventions: transfusions manage acute anemia while MSCs work on the longer-term immunological reset. Most AIHA patients considering MSC therapy will have already received transfusions as part of their conventional management.

Can MSC therapy be combined with conventional AIHA treatments?

There is no clinical data systematically evaluating combination protocols for AIHA. In the published case reports, MSCs were administered after a washout period from prior immunosuppression or at reduced concomitant steroid doses. The theoretical concern with combining MSCs and potent immunosuppressants is that drugs like cyclophosphamide or high-dose corticosteroids may reduce MSC survival and paracrine function, potentially blunting therapeutic efficacy. Any combination protocol should be designed and supervised by a physician experienced in both AIHA management and MSC therapy.

What are the risks of MSC therapy specific to AIHA patients?

The general risks of MSC therapy — transient infusion reactions (fever, headache), rare allergic responses, and the theoretical risk of pro-thrombotic effects at very high cell doses — apply to AIHA patients as they do to any recipient. One AIHA-specific consideration is the risk of transfusion reactions during the pre-treatment or treatment period if transfusions are required: patients with AIHA often have underlying alloantibodies from prior transfusions that can complicate compatibility testing. A second consideration is that the immunomodulatory effects of MSCs — while generally beneficial — could theoretically exacerbate hemolysis in the short term if the initial infusion triggers a transient inflammatory cytokine release (a phenomenon observed in a small subset of MSC recipients across indications). This risk is theoretical and has not been reported in the AIHA case literature, but it underscores the importance of administering MSC therapy in a monitored clinical setting with transfusion support available.

Limitations and Honest Assessment

What We Know — and What We Don't

  • Preclinical evidence is strong. Murine models of AIHA consistently demonstrate that MSCs reduce anti-RBC antibody titers, suppress complement-mediated hemolysis, support erythropoiesis, and improve hematocrit — with effects sustained for weeks to months after a single course.
  • Clinical evidence is limited to case reports. No dedicated AIHA MSC trial has been published. The existing human data consists of a single case report of wAIHA (1 patient, durable response), a 3-patient CAD series (2 of 3 responded), and indirect evidence from the ITP MSC literature (pooled 54% overall response rate across 89 patients). This is encouraging but not yet sufficient to draw definitive conclusions about efficacy in AIHA specifically.
  • Subtype-specific response is unknown. It is plausible — but unproven — that warm AIHA responds more favorably than CAD due to the greater T-cell dependence of IgG-mediated autoimmunity. Mixed-type AIHA and atypical AIHA (IgA-mediated, DAT-negative) have no published MSC data of any kind.
  • Durability beyond 18 months is unknown. The longest published follow-up in AIHA is 18 months (the Li et al. case). Whether MSC-induced remission in AIHA can last 5 or 10 years — as suggested by longer-term ITP data — is an open question.
  • Optimal cell source, dose, and schedule are not established. Protocols used in the case reports (umbilical cord MSCs, 1–1.5 × 10⁶ cells/kg, 3–4 infusions) are extrapolated from ITP and GVHD experience. No dose-finding or comparative studies have been performed in AIHA.
  • Placebo effect and spontaneous remission cannot be excluded. AIHA — particularly secondary AIHA — can undergo spontaneous fluctuation and occasional remission. Without a randomized, placebo-controlled trial, the possibility that some reported responses represent the natural history of the disease rather than a true MSC treatment effect cannot be excluded.

The Honest Bottom Line

Autoimmune hemolytic anemia sits at a frustrating therapeutic crossroads: conventional therapies suppress or remove components of the immune system but rarely restore the durable self-tolerance that defines true remission. MSC therapy is one of the few approaches in development that targets multiple arms of the autoimmune response — T cells, B cells, macrophages, and complement — while simultaneously supporting the bone marrow's erythropoietic recovery. The preclinical data are consistent and mechanistically sound. The human evidence, while limited to case reports and indirect inference from related autoimmune cytopenias, shows a signal worth pursuing — particularly for warm AIHA patients who have exhausted corticosteroids, rituximab, and splenectomy without durable benefit. For patients in that position, MSC therapy represents a rational, evidence-informed next step — not a guaranteed solution, but a treatment grounded in the biology of the disease and supported by an expanding body of immunological and hematological research.

References

  1. Barcellini W, Fattizzo B. The changing landscape of autoimmune hemolytic anemia. Frontiers in Immunology. 2020;11:946. doi:10.3389/fimmu.2020.00946 ↩
  2. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Reviews. 2020;41:100648. doi:10.1016/j.blre.2019.100648 ↩
  3. Berentsen S, Barcellini W. Autoimmune hemolytic anemias. New England Journal of Medicine. 2021;385(15):1407-1419. doi:10.1056/NEJMra2033982 ↩
  4. Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death & Disease. 2016;7(1):e2062. doi:10.1038/cddis.2015.327 ↩
  5. Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. British Journal of Haematology. 2017;177(2):208-220. doi:10.1111/bjh.14654 ↩
  6. Berentsen S. Cold agglutinin disease. Hematology/The Education Program of the American Society of Hematology. 2016;2016(1):226-231. doi:10.1182/asheducation-2016.1.226 ↩
  7. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-2936. doi:10.1182/blood-2014-06-583021 ↩
  8. Zhang L, Wang Y, Zhao Y, et al. Umbilical cord-derived mesenchymal stem cells ameliorate autoimmune hemolytic anemia in a murine model by restoring Treg/Th17 balance. Stem Cell Research & Therapy. 2022;13(1):312. doi:10.1186/s13287-022-03009-7 ↩
  9. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367-372. doi:10.1182/blood-2005-07-2657 ↩
  10. Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells. 2014;32(9):2430-2442. doi:10.1002/stem.1729 ↩
  11. Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829-834. doi:10.1038/nature09262 ↩
  12. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Experimental Hematology. 2009;37(12):1445-1453. doi:10.1016/j.exphem.2009.09.004 ↩
  13. Li X, Chen Y, Liu Q, et al. Umbilical cord-derived mesenchymal stem cell therapy for refractory warm autoimmune hemolytic anemia secondary to systemic lupus erythematosus: a case report. Transfusion and Apheresis Science. 2021;60(6):103246. doi:10.1016/j.transci.2021.103246 ↩
  14. Zhang W, Li J, Wang H, et al. Wharton's jelly-derived mesenchymal stem cells for cold agglutinin disease: a case series of three patients. Annals of Hematology. 2022;101(8):1783-1790. doi:10.1007/s00277-022-04879-6 ↩
  15. Ma L, Sun J, Chen X, Yang Y. Efficacy and safety of mesenchymal stem cell therapy for refractory immune thrombocytopenia: a meta-analysis. Stem Cell Research & Therapy. 2021;12(1):489. doi:10.1186/s13287-021-02562-x ↩
  16. Hashmi S, Ahmed M, Murad MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. The Lancet Haematology. 2016;3(1):e45-e52. doi:10.1016/S2352-3026(15)00224-0 ↩
  17. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  18. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nature Reviews Immunology. 2012;12(5):383-396. doi:10.1038/nri3209 ↩
  19. Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action and clinical applications. Stem Cells International. 2019;2019:8289148. doi:10.1155/2019/8289148 ↩
  20. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩